Cocoon Biotech Information

Cocoon Biotech, Inc., was founded in 2013 to bring the freedom of living a healthy productive life to patients worldwide. Cocoon Biotech is developing a drug-delivery platform based on formulations of fibroin, a protein derived from the cocoon of the silkworm (Bombyx mori). Recent advances in our understanding of fibroin biochemistry has allowed expansion of the versatility of the material into alternate physical formats such as hydrogels and implants loaded with active drug substances. Cocoon is leveraging silk fibroin as a novel biomaterial for the stability and delivery of therapeutics across human health and animal health. Cocoon’s first products are silk fibroin formulated with small molecules that target pain and inflammation in ophthalmology and osteoarthritis indications.